MKI67 and breast cancer: In addition, The American College of Surgeons Oncology Group Z1031 (ACOSOG Z1031) trial (6) has shown that Ki-67 index at 2 weeks of treatment is significantly associated with recurrence-free survival, and it can predict the prognosis of BC patients undergoing neoadjuvant endocrine therapy (NET).